Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Semaglutide for weight loss is dosed once weekly by subcutaneous injection in the FDA label for Wegovy, with 4-week steps from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg [1]. The FDA-approved recommended maintenance dose is 2.4 mg once weekly, while slower titration may reduce stomach side effects [1].
Quick facts: semaglutide weight loss dosing at a glance
Semaglutide weight-loss dosing is usually discussed from the Wegovy FDA label, which uses 4-week dose-escalation steps to help patients reach a maintenance dose while monitoring tolerability [1]. The same section of the label lists common side effects and warnings, including gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury, and contraindication in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1].
| Dose phase | FDA-labeled Wegovy dose | Timing in FDA label | Why this step exists |
|---|---|---|---|
| Initiation | The FDA label lists 0.25 mg once weekly | Weeks 1–4 | The label describes this as the starting step in dose escalation, not the maintenance dose [1] |
| Escalation 1 | The FDA label lists 0.5 mg once weekly | Weeks 5–8 | The label continues gradual escalation to support tolerability [1] |
| Escalation 2 | The FDA label lists 1.0 mg once weekly | Weeks 9–12 | The label continues gradual escalation toward maintenance [1] |
| Escalation 3 | The FDA label lists 1.7 mg once weekly | Weeks 13–16 | The label lists 1.7 mg once weekly as an escalation step and as a maintenance option if 2.4 mg is not tolerated [1] |
| Maintenance | The FDA label lists 2.4 mg once weekly as the recommended maintenance dose | Week 17 and after | The FDA-approved recommended maintenance dose for chronic weight management is 2.4 mg once weekly [1] |
What is semaglutide and how does it cause weight loss?
Semaglutide is a GLP-1 receptor agonist, meaning it acts on the same receptor as the gut hormone glucagon-like peptide-1 [1]. It can reduce appetite and food intake in clinical studies, but side effects and contraindications must be weighed before use [1,2].
Mechanism: GLP-1 receptor agonism
Semaglutide is the international nonproprietary name for a GLP-1 receptor agonist, a medicine class that affects appetite, satiety, gastric emptying, and glucose regulation [1]. In STEP 1, participants receiving semaglutide 2.4 mg once weekly plus lifestyle intervention had greater average weight loss than participants receiving placebo plus lifestyle intervention over 68 weeks; individual results varied, and gastrointestinal events were more common with semaglutide [2].
The Wegovy FDA label includes important safety limits along with the weight-management indication. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with multiple endocrine neoplasia syndrome type 2, and people with a serious hypersensitivity reaction to semaglutide or any product ingredient [1].
Brand vs generic vs compounded semaglutide
Wegovy is semaglutide, a GLP-1 receptor agonist, and is FDA-approved for chronic weight management in eligible patients [1]. Ozempic is also semaglutide and is FDA-approved for type 2 diabetes and certain cardiovascular and kidney risk indications, not for weight loss; using Ozempic for weight loss is off-label and should be reviewed by a clinician [7].
Compounded semaglutide via a 503A pharmacy is not FDA-approved. A state-licensed 503A pharmacy may prepare a compounded medication for an individual patient based on a valid prescription when federal and state requirements are met, but compounded drugs do not go through FDA premarket review for safety, effectiveness, or quality [8].
What is the standard semaglutide dose schedule for weight loss?
The standard reference point is the Wegovy FDA label, which lists once-weekly dose escalation in 4-week steps [1]. This is label information, not a personal dosing plan, and a clinician may adjust timing when side effects or health history make that appropriate [1].
Week-by-week titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg
The FDA label for Wegovy lists a once-weekly titration schedule that includes 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and 2.4 mg at week 17 and after [1]. The same label states that 2.4 mg once weekly is the recommended maintenance dose, and 1.7 mg once weekly is another maintenance option if 2.4 mg is not tolerated [1].
| Weeks in Wegovy FDA label | FDA-labeled Wegovy dose | Purpose in label |
|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly is listed in the FDA label | Initiation step in dose escalation, not the maintenance dose [1] |
| Weeks 5–8 | 0.5 mg once weekly is listed in the FDA label | Dose-escalation step [1] |
| Weeks 9–12 | 1.0 mg once weekly is listed in the FDA label | Dose-escalation step [1] |
| Weeks 13–16 | 1.7 mg once weekly is listed in the FDA label | Dose-escalation step and possible maintenance option if 2.4 mg is not tolerated [1] |
| Week 17 and after | 2.4 mg once weekly is listed in the FDA label as the recommended maintenance dose | Recommended maintenance dose for chronic weight management [1] |
Why doctors titrate slowly
Doctors titrate semaglutide slowly because gastrointestinal side effects are common with GLP-1 receptor agonists [1]. The Wegovy label lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and reflux among common adverse reactions [1].
Maintenance dose and how long people stay on it
The FDA label describes Wegovy as a chronic weight-management medication for eligible patients, not a short course [1]. In STEP 4, participants who continued semaglutide 2.4 mg once weekly after a 20-week run-in period had better average weight outcomes than participants switched to placebo, but gastrointestinal adverse events still occurred and individual results varied [3].
How does compounded semaglutide dosing compare to Wegovy?
Wegovy has an FDA-approved dosing label; compounded semaglutide does not [1,8]. If a clinician prescribes compounded semaglutide, the product may have a different concentration, container, or measuring device, so the pharmacy label and clinician instructions matter for safety [8].
Compounded semaglutide is not FDA-approved, while Wegovy has an FDA-approved chronic weight-management label with a recommended maintenance dose of 2.4 mg once weekly [1,8]. FDA has warned about dosing errors and about some compounded products that use semaglutide salt forms, which are different active ingredients than the semaglutide base used in approved products [8].
| Question | Wegovy | Compounded semaglutide |
|---|---|---|
| FDA status | FDA-approved for chronic weight management in eligible patients [1] | Not FDA-approved; prepared for an individual patient under a prescription when compounding requirements are met [8] |
| Active ingredient | Semaglutide [1] | Should be prescribed as semaglutide; FDA has raised concerns about some compounded semaglutide salt forms [8] |
| Dosing reference | The FDA label lists 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg once weekly in 4-week steps [1] | No FDA-approved dosing label; clinician and pharmacy label determine the patient-specific prescription [8] |
| Quality review | FDA-reviewed before approval for safety, effectiveness, and quality [1] | Compounded drugs are not FDA-approved and do not receive FDA premarket review for safety, effectiveness, or quality [8] |
| Packaging | Single-dose pen presentation described in the FDA label [1] | May be supplied differently, so measuring and injection instructions must be reviewed carefully [8] |
How do I inject semaglutide and when should I take it?
The Wegovy FDA label states that semaglutide is administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm [1]. Injection timing can be flexible, but technique and product-specific instructions are important for safety [1,8].
Injection sites and technique
The FDA label says Wegovy is given by subcutaneous injection in the abdomen, thigh, or upper arm once weekly [1]. The label also says the injection site should be changed with each injection and that Wegovy should not be injected into a muscle or vein [1].
For compounded semaglutide, patients should review the pharmacy label, device instructions, and clinician instructions before use because compounded products may be supplied differently than a Wegovy pen [8]. This matters because FDA has received reports of dosing errors with compounded injectable semaglutide products [8].
Best day of the week and timing
The Wegovy label states that semaglutide may be administered once weekly at any time of day, with or without meals [1]. The label also states that the day of weekly administration may be changed if the time between 2 doses is at least 48 hours [1].
What if I miss a dose or need to pause?
The Wegovy label gives missed-dose rules based on how soon the next scheduled dose is due [1]. If the situation is unclear, a clinician or pharmacist should help, especially after a longer pause or if side effects caused the missed dose [1].
Missed dose rules from the FDA label
For Wegovy, the FDA label gives specific missed-dose instructions based on whether the next scheduled dose is more than 2 days away [1]. These are label instructions for the product, not individualized medical advice [1].
- If 1 Wegovy dose is missed and the next scheduled dose is more than 2 days away, the FDA label says to administer Wegovy as soon as possible [1].
- If 1 Wegovy dose is missed and the next scheduled dose is less than 2 days away, the FDA label says to skip the missed dose and administer the next dose on the regularly scheduled day [1].
- If more than 2 consecutive Wegovy doses are missed, the FDA label says to resume dosing as scheduled or, if needed, reinitiate and follow the dose-escalation schedule to reduce gastrointestinal symptoms [1].
Restarting after a longer break
After a longer pause, nausea or vomiting may be more likely if semaglutide is restarted without considering tolerability, which is why the FDA label allows reinitiation and dose escalation after more than 2 missed doses when needed [1]. A licensed clinician should review the reason for the pause, current medicines, pregnancy status, diabetes medicines, and warning symptoms before a restart plan [1].
What side effects should I expect at each dose?
Side effects can happen at any dose, but they are commonly discussed during escalation because the Wegovy label increases the dose every 4 weeks [1]. Benefits should be weighed with side effects, contraindications, and warning signs at every follow-up [1].
Common GI side effects
Semaglutide side effects can happen at any dose, including the 4-week escalation phases in the Wegovy label [1]. Common adverse reactions in the label include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and reflux [1].
| Dose phase in Wegovy label | Side effects to watch for | Why clinician follow-up matters |
|---|---|---|
| 0.25 mg once weekly is listed in the FDA label as the initiation step | Nausea, fullness, constipation, or reflux may begin [1] | This is not the FDA-approved maintenance dose for chronic weight management [1] |
| 0.5 mg and 1.0 mg once weekly are listed in the FDA label as escalation steps | GI symptoms may continue or increase during escalation [1] | A clinician can review hydration, food intake, other medicines, and warning signs [1] |
| 1.7 mg once weekly is listed in the FDA label as an escalation step and maintenance option | Nausea, vomiting, diarrhea, or abdominal pain may affect tolerability [1] | The FDA label allows 1.7 mg once weekly as a maintenance option if 2.4 mg is not tolerated [1] |
| 2.4 mg once weekly is listed in the FDA label as the recommended maintenance dose | GI symptoms can still occur at maintenance [1] | Benefits, side effects, contraindications, and labs when needed should be reviewed over time [1] |
When to slow the titration
The Wegovy label states that if patients do not tolerate a dose during escalation, clinicians may consider delaying dose escalation for 4 weeks [1]. This decision should be individualized because persistent vomiting, dehydration, low blood sugar risk, gallbladder symptoms, kidney injury risk, and other issues may change the risk-benefit balance [1].
Warning signs that need a clinician
The Wegovy label includes warnings and precautions for thyroid C-cell tumor risk, acute pancreatitis, acute gallbladder disease, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury, serious allergic reactions, increased heart rate, suicidal behavior or thinking, and pulmonary aspiration during anesthesia or deep sedation [1]. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Wegovy, according to the boxed warning [1].
When will I see weight loss results on semaglutide?
Clinical trials measured semaglutide weight outcomes over months, not days [2-5]. Results vary, and any weight-change discussion should include side effects, contraindications, nutrition, activity, and follow-up because semaglutide is not appropriate for everyone [1,2].
STEP trial timeline
In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly plus lifestyle intervention for 68 weeks and had greater average weight loss than participants receiving placebo plus lifestyle intervention; individual results varied, and nausea, diarrhea, vomiting, and constipation were more frequent with semaglutide [2]. In STEP 5, participants receiving semaglutide 2.4 mg once weekly had weight-loss outcomes sustained over 104 weeks, with gastrointestinal adverse events commonly reported [4].
What “good response” looks like at 16 weeks
Clinical response is usually judged by a clinician using weight change, side effects, labs when needed, blood pressure, health conditions, and patient goals [1]. In the Wegovy label, adult eligibility is based on body mass index criteria: BMI of 30 kg/m2 or higher, or BMI of 27 kg/m2 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1].
Tirzepatide is a different injectable medicine that activates GIP and GLP-1 receptors and is FDA-approved as Zepbound for chronic weight management in eligible patients [9]. In SURMOUNT-1, participants receiving tirzepatide 5 mg, 10 mg, or 15 mg once weekly had greater average weight loss than participants receiving placebo over 72 weeks; gastrointestinal adverse events were common, and this does not show which medicine is right for an individual patient [10].
How do I get a semaglutide prescription and what does it cost?
Semaglutide for weight management requires a prescription and a clinical review of eligibility, risks, and alternatives [1]. Cost varies by insurance coverage, pharmacy, product type, follow-up model, and whether the medication is FDA-approved Wegovy or a compounded option [1,8].
Semaglutide eligibility often starts with BMI criteria such as BMI 30 kg/m2 or higher, or BMI 27 kg/m2 or higher with a weight-related condition, as listed in the Wegovy label [1]. A clinician should also review contraindications, pregnancy plans, diabetes medicines, gallbladder or pancreas history, kidney risk, mental health history, upcoming anesthesia, and other medications before prescribing [1].
Access paths may include an in-person primary care clinician, an obesity-medicine clinic, an endocrinologist, or a licensed telehealth provider. Chia is one option for a clinician-reviewed telehealth evaluation that may include compounded GLP-1 medications from licensed 503A pharmacy partners when appropriate; compounded semaglutide is not FDA-approved and must be prescribed for an individual patient under applicable law [8].
When comparing cost, patients should look at the full monthly picture: medication price, insurance coverage, visit fees, lab needs, refill process, pharmacy source, and clinical support. FDA notes that compounded drugs are not FDA-approved and do not receive FDA premarket review, so source and clinician oversight are part of the safety review [8].
3-min quiz
Considering semaglutide?
A licensed clinician can review your health history, goals, medications, eligibility, and safety considerations before any prescription decision.
Frequently asked questions
For Wegovy, the FDA-approved recommended maintenance dose for chronic weight management is 2.4 mg once weekly; the label also lists 1.7 mg once weekly as a maintenance option if 2.4 mg is not tolerated [1].
The Wegovy FDA label lists 4-week steps: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg once weekly, so the 2.4 mg maintenance dose is reached around week 17 if escalation is tolerated [1].
The Wegovy label lists 2.4 mg once weekly as the recommended maintenance dose and 1.7 mg once weekly as another maintenance option if 2.4 mg is not tolerated [1]. Whether a lower dose is appropriate is a medical decision for a licensed clinician.
No. Wegovy is FDA-approved semaglutide for chronic weight management [1]. Compounded semaglutide is not FDA-approved, does not undergo FDA premarket review, and may differ in concentration, packaging, and instructions [8].
No. Ozempic is semaglutide, but its FDA label is for type 2 diabetes and certain cardiovascular and kidney risk indications, not weight loss [7]. Weight-loss use of Ozempic is off-label and should be discussed with a clinician.
For Wegovy, the FDA label gives missed-dose rules based on how soon the next scheduled dose is due and says reinitiation with dose escalation may be considered after more than 2 missed doses to reduce gastrointestinal symptoms [1]. Ask a clinician or pharmacist if you are unsure.
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether treatment is appropriate.
Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates GIP and GLP-1 receptors [1,9]. Both have FDA-approved chronic weight-management products for eligible patients, and both can cause gastrointestinal side effects and have important warnings [1,9].
3-min quiz
Talk with a clinician about your options
If you are considering semaglutide, a clinical evaluation can help clarify eligibility, safety, cost, and whether an FDA-approved or compounded option is appropriate.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration, 2024.
- 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
- 3.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021.
- 4.Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022.
- 5.Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 2021.
- 6.Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes: the STEP 2 randomized clinical trial. The Lancet, 2021.
- 7.Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration, 2025.
- 8.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2025.
- 9.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration, 2024.
- 10.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
